Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM9T6MS)

• Drug Name: Tecadenoson Drug Info
• Synonyms: CVT-510; 204512-90-3; UNII-GZ1X96601Z; CHEMBL392149; GZ1X96601Z; (2R,3S,4R,5R)-2-(hydroxymethyl)-5-[6-[[(3R)-oxolan-3-yl]amino]purin-9-yl]oxolane-3,4-diol; BDBM50224766; Tecadenoson [USAN:INN]; Tecadenoson (USAN/INN); AC1L4KMO; SCHEMBL246787; GTPL5592; CHEMBL356254; DTXSID80174415; BDBM50138530; DB04954; N6-[3-(R)-tetrahydrofuranyl]adenosine; HY-19661; Adenosine, N-(3R)-tetrahydro-3-furanyl-; LS-190860; Adenosine, N-(3R)-tetrahydro-3-furanyl)-; CS-0016174; D06019; CVT-510; N-(3-Tetrahydrofuranyl)-6-aminopurine riboside; Selenocompounds

Indication

Disease Entry	ICD 11	Status	REF
Atrial fibrillation	BC81.3	Discontinued in Phase 3	[1]
Cardiac arrhythmias	BC9Z	Discontinued in Phase 3	[1]

• Cross-matching ID:
  PubChem CID: 158795
  CAS Number: CAS 204512-90-3
  TTD Drug ID: DM9T6MS
  VARIDT Drug ID: DR00923

Molecule-Related Drug Atlas

Drug(s) Targeting Protein kinase C (PRKC)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Synthetic hypericin	DMXU4ON	Virus infection	1A24-1D9Z	Phase 3	[5]
APH-0812	DM756GE	Human immunodeficiency virus-1 infection	1C62	Phase 2	[6]
CYCLOPLATAM	DMXR8WN	Solid tumour/cancer	2A00-2F9Z	Phase 2	[7]
AEB07	DMJVN89	Transplant rejection	NE84	Phase 2	[8]
HO/03/03	DMA6HQJ	Diabetic foot ulcer	BD54	Phase 2	[9]
Bryostatin-1	DM1JOXY	Alzheimer disease	8A20	Phase 2	[10]
LXS196	DM65MEL	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[11]
SAFINGOL	DMBGUDR	Psoriasis vulgaris	EA90	Phase 1	[12]
GCC-1290K	DMJ7WRI	Parkinson disease	8A00.0	Phase 1	[13]
AEB701	DM8I4G0	Melanoma	2C30	Phase 1	[14]

Drug(s) Targeting Adenosine A1 receptor (ADORA1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Caffeine	DMKBJWP	Allergic rhinitis	CA08.0	Approved	[15]
Rolofylline	DMSZPR3	Heart failure	BD10-BD13	Phase 3	[16]
Tonapofylline	DMBH316	Acute and chronic heart failure	BD1Z	Phase 2	[17]
AMP-579	DMJ4GPR	Hyperlipidaemia	5C80	Phase 2	[18]
SELODENOSON	DMQM3IX	Cardiac arrhythmias	BC9Z	Phase 2	[19]
Apaxifylline	DMQMV9F	Cognitive impairment	6D71	Phase 2	[20]
SLV320	DM867BJ	Heart failure	BD10-BD13	Phase 2	[21]
DTI-0009	DMV84OK	Atrial fibrillation	BC81.3	Phase 2	[19]
Capadenoson	DMYWO62	Atrial fibrillation	BC81.3	Phase 2	[22]
BAY 1067197	DM4JGNH	Heart failure	BD10-BD13	Phase 2	[23]

Drug(s) Transported By Equilibrative nucleoside transporter 1 (SLC29A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[24]
Mercaptopurine	DMTM2IK	Acute lymphoblastic leukaemia	2A85	Approved	[25]
Cytarabine	DMZD5QR	Acute lymphoblastic leukaemia	2A85	Approved	[26]
Entecavir	DM7VTQO	Hepatitis B virus infection	1E51.0	Approved	[27]
Ribavirin	DMEYLH9	Hepatitis C virus infection	1E51.1	Approved	[28]
Clofarabine	DMCVJ86	Acute lymphoblastic leukaemia	2A85	Approved	[29]
Trifluridine	DMG2YBD	Herpetic keratitis	1F00.10	Approved	[30]
Adenosine	DMM2NSK	Paroxysmal supraventricular tachycardia	BC81.Z	Approved	[31]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Adenosine A1 receptor (ADORA1)	TTK25J1	AA1R_HUMAN	Agonist	[2]
Protein kinase C (PRKC)	TTYVX59	NOUNIPROTAC	Binder	[3]

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Equilibrative nucleoside transporter 1 (SLC29A1)	DTXD1TQ	S29A1_HUMAN	Substrate	[4]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5592).
• [2] CV Therapeutics. Company report from CV Therapeutics, Inc. CV Therapeutics. 2009.
• [3] Protein kinase C as a molecular target for cancer prevention by selenocompounds. Nutr Cancer. 2001;40(1):55-63.
• [4] Transport of A1 adenosine receptor agonist tecadenoson by human and mouse nucleoside transporters: evidence for blood-brain barrier transport by murine equilibrative nucleoside transporter 1 mENT1. Drug Metab Dispos. 2013 Apr;41(4):916-22.
• [5] Characterization of the interaction of hypericin with protein kinase C in U-87 MG human glioma cells. Photochem Photobiol. 2006 May-Jun;82(3):720-8.
• [6] Targeting the protein kinase C family: are we there yet. Nat Rev Cancer. 2007 Jul;7(7):554-62.
• [7] Effect of anti-tumor agents cisplatin and cycloplatam on membrane protein kinase C activity in murine T-lymphocytes. Biokhimiia. 1996 Oct;61(10):1866-73.
• [8] What's next in the pipeline. Am J Transplant. 2008 Oct;8(10):1972-81.
• [9] WO patent application no. 2014,0853,81, Pharmaceutical combinations.
• [10] Bryostatin-1: a promising compound for neurological disorders. Front Pharmacol. 2023 Jun 7;14:1187411.
• [11] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [12] The role of protein kinase C in the synergistic interaction of safingol and irinotecan in colon cancer cells. Int J Oncol. 2009 Dec;35(6):1463-71.
• [13] Inhibitory effect of glutamate release from rat cerebrocortical synaptosomes by dextromethorphan and its metabolite 3-hydroxymorphinan. Neurochem Int. 2009 Jul;54(8):526-34.
• [14] Changes in Serum Cytokine Profile after AEB071 (Sotrastaurin) or Tacrolimus versus Their Combinations in Rat Heterotopic Cardiac Allografts. J Korean Soc Transplant. 2012 Dec;26(4):248-253.
• [15] Caffeine as a psychomotor stimulant: mechanism of action. Cell Mol Life Sci. 2004 Apr;61(7-8):857-72.
• [16] Association between the PDE4D gene and ischaemic stroke in the Chinese Han population. Clin Sci (Lond). 2009 Aug 17;117(7):265-72.
• [17] 2-Amino-5-benzoyl-4-phenylthiazoles: Development of potent and selective adenosine A1 receptor antagonists. Bioorg Med Chem. 2010 Mar 15;18(6):2195-2203.
• [18] Adenosine A1/A2a receptor agonist AMP-579 induces acute and delayed preconditioning against in vivo myocardial stunning. Am J Physiol Heart Circ Physiol. 2004 Dec;287(6):H2746-53.
• [19] Recent developments in adenosine receptor ligands and their potential as novel drugs. Biochim Biophys Acta. 2011 May;1808(5):1290-308.
• [20] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004779)
• [21] Role of matrix metalloproteinases and their tissue inhibitors as potential biomarkers of left ventricular remodelling in the athlete's heart. Clin Sci (Lond). 2009 Jul 16;117(4):157-64.
• [22] A1 adenosine receptor agonists and their potential therapeutic applications. Expert Opin Investig Drugs. 2008 Dec;17(12):1901-10.
• [23] Separation of on-target efficacy from adverse effects through rational design of a bitopic adenosine receptor agonist. Current Issue vol. 111 no. 12 Celine Valant, 4614-4619.
• [24] Human equilibrative nucleoside transporter 1, as a predictor of 5-fluorouracil resistance in human pancreatic cancer. Anticancer Res. 2007 Jul-Aug;27(4B):2241-9.
• [25] PharmGKB: A worldwide resource for pharmacogenomic information. Wiley Interdiscip Rev Syst Biol Med. 2018 Jul;10(4):e1417. (ID: PA2040)
• [26] FLT3 is implicated in cytarabine transport by human equilibrative nucleoside transporter 1 in pediatric acute leukemia. Oncotarget. 2016 Aug 2;7(31):49786-49799.
• [27] Multiple SLC and ABC Transporters Contribute to the Placental Transfer of Entecavir. Drug Metab Dispos. 2017 Mar;45(3):269-278.
• [28] Effects of dipyridamole coadministration on the pharmacokinetics of ribavirin in healthy volunteers. Drug Metab Pharmacokinet. 2013;28(5):406-10.
• [29] Cytarabine-resistant leukemia cells are moderately sensitive to clofarabine in vitro. Anticancer Res. 2014 Apr;34(4):1657-62.
• [30] Lonsurf, INN-trifluridine/tipiracil.
• [31] Nitric oxide reduces adenosine transporter ENT1 gene (SLC29A1) promoter activity in human fetal endothelium from gestational diabetes. J Cell Physiol. 2006 Aug;208(2):451-60.